首页> 美国卫生研究院文献>Technology in Cancer Research Treatment >The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma
【2h】

The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma

机译:胶质母细胞瘤中肿瘤浸润性免疫细胞和免疫检查点的预后景观

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor-infiltrating immune cells are part of a complex microenvironment and associated with improved clinical outcomes in a broad range of tumor types. However, a detailed map for the prognostic landscape of tumor-infiltrating immune cells and immune checkpoint modulators in glioblastoma is still lacking. Here, with the web-accessible resource, The Cancer Immunome Archive, 28 types of both adaptive and innate tumor-infiltrating immune cells were characterized in glioblastoma. Tumors lacking central memory CD4 T cells or natural killer cells were associated with better prognosis in glioblastoma, as verified by immunohistochemical analysis. Moreover, Kaplan-Meier analysis for a total of 71 key immune checkpoint molecules revealed that the expression level of inducible T cell costimulators, tumor necrosis factor superfamily member 14, and UL16 binding protein 1 were negatively correlated with the clinical outcome of patients with glioblastoma. In addition, there was a significant difference between nontumor and glioblastoma samples of several immune checkpoint modulators based on the expression level of their corresponding gene. Collectively, the annotation of tumor-infiltrating immune cells and immune checkpoint modulators in glioblastoma provides a valuable resource for identifying their involvement in tumor escape mechanisms and response to therapy.
机译:肿瘤浸润免疫细胞是复杂的微环境的一部分,并与广泛的肿瘤类型的改善的临床结果相关。但是,仍然缺乏胶质母细胞瘤中肿瘤浸润性免疫细胞和免疫检查点调节剂预后情况的详细图谱。在这里,利用可通过网络访问的资源《癌症免疫组学档案》,在胶质母细胞瘤中鉴定了28种类型的适应性和先天性肿瘤浸润免疫细胞。免疫组织化学分析证实,缺乏中央记忆CD4 T细胞或自然杀伤细胞的肿瘤与胶质母细胞瘤的预后较好有关。此外,对总共71个关键免疫检查点分子的Kaplan-Meier分析显示,诱导性T细胞共刺激因子,肿瘤坏死因子超家族成员14和UL16结合蛋白1的表达水平与胶质母细胞瘤患者的临床结果呈负相关。另外,基于相应基因的表达水平,几种免疫检查点调节剂的非肿瘤和胶质母细胞瘤样品之间存在显着差异。总的来说,胶质母细胞瘤中肿瘤浸润性免疫细胞和免疫检查点调节剂的注释为鉴定其参与肿瘤逃逸机制和对治疗的反应提供了宝贵的资源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号